Earnings NYSE Nasdaq 100 U.S. Tech Politics Science AI SEC Business Wall Street Energy Dow Jones Dividend Bitcoin (BTC) Markets NVIDIA (NVDA) Investing Economy S&P 500 China Donald Trump Fed World Crude Oil Tesla (TSLA) Inflation Money Gold Software Apple (AAPL) U.K. Wealth Entertainment Health Amazon (AMZN) Retail 3M (MMM) Real Estate Taxes Europe Natural Gas Elon Musk Microsoft (MSFT) Security Meta Platforms (META) Retirement Truist Financial Corp (TFC) Canada Current Boeing (BA) Options Jim Cramer Hedge Funds Insurance Tax Sports Live Google Economics Manufacturing Pharmaceuticals Cars Mining Costco (COST) Airlines Warren Buffett War Japan Silver Construction Interest Rates York Ukraine BlackRock (BLK) New York Holidays Kamala Harris Finance Goldman Sachs (GS) REITs Space Mortgage KeyCorp (KEY) Internet Walmart (WMT) Aerospace JPMorgan (JPM) Ethereum (ETH) Intel (INTC) Walt Disney (DIS) Enterprise OpenAI ChatGPT GBP USD Netflix (NFLX) Australia Boston Morgan Stanley (MS) IndiaMore +
Market Insider Market Insider
  • Stocks
  • ETFs
  • Bonds
  • Commodities
  • Earnings
  • Dividends
  • REITs
  • IPOs
  • Cryptocurrency
  • Forex
  • Tech
  • Politics
  • +

2 weeks Gilead increases 2024 outlook, expects new drug filing by end of yearYahoo Finance

Gilead increases 2024 outlook, expects new drug filing by end of year.

Gilead (GILD)

X       

20 hours Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)Seeking Alpha X       

2 days Market Digest: ADTN, EQR, GILD, NFG, PRU, MSCIYahoo Finance X       

7 days Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a BetZacks X       

1 week GILD or VRTX: Which Is the Better Value Stock Right Now?Zacks X       

2 weeks Gilead Beats on Q3 Earnings and Sales, Raises Annual OutlookZacks X       

2 weeks Why Gilead’s Solid Q3 Earnings Could Point To A Dividend Surprise Next YearSeeking Alpha X       

2 weeks Gilead Sciences (GILD) Q3 2024 Earnings Call TranscriptThe Motley Fool X       

2 weeks Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And RaiseInvestor's Business Daily X       

2 weeks Gilead’s third-quarter earnings beat by a wide margin, and biotech raises guidanceMarketWatch X       

2 weeks Gilead Science to Report Q3 Earnings: What’s in the Cards?Zacks X       

3 weeks Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowZacks X       

3 weeks Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by New York State Teachers Retirement SystemMarketBeat X       

3 weeks Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to DeclineZacks X       

3 weeks Gilead Sciences (GILD) Stock Sinks As Market Gains: Here’s WhyZacks X       

3 weeks Gilead Sciences (NASDAQ:GILD) Given Sector Perform Rating at Royal Bank of CanadaMarketBeat X       

4 weeks Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of “Moderate Buy” by BrokeragesMarketBeat X       

4 weeks Why Gilead Sciences (GILD) Dipped More Than Broader Market TodayZacks X       

4 weeks Gilead Sciences (NASDAQ:GILD) Sets New 12-Month High – Still a Buy?MarketBeat X       

1 month Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by Leerink PartnrsMarketBeat X       

1 month Gilead, MRK Report Data From Investigational Combination Study for HIVZacks X       

1 month Calls of the Day: Gilead, Berkshire Hathaway and SLBYouTube X       

1 month Crew Capital Management Ltd. Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)MarketBeat X       

1 month Gilead Sciences (NASDAQ:GILD) Upgraded by Leerink Partners to OutperformMarketBeat X       

1 month Stratos Investment Management LLC Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)MarketBeat X       

1 month Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROEInsider Monkey X       

More news +
Home | Contact
  • X

© 2024 Market Insider